N.Y. Judge Orders Fosamax Plaintiffs to Specify When They Took Teva’s Generic Equivalent

NEW YORK — The judge overseeing the Fosamax multidistrict litigation has ordered plaintiffs in five cases to amend their pleadings to specify when they took Teva Pharmaceutical Co.’s generic version, explaining that Teva needs the information in order to respond to their failure-to-update claims.

On Dec. 18, Judge John F. Keenan of the U.S. District Court for the Southern District of New York found Teva has successfully shown that the period of ingestion by each plaintiff constitutes “a substantial threshold question that may be dispositive."

This multidistrict litigation involves claims that Merck’s Fosamax and its generic equivalent, alendronate sodium, …